Mirvetuximab soravtansine (solution)

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141) . Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1) . Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].

Product Specifications

CAS Number

[1453084-37-1]

Product Name Alternative

IMGN853 (solution)

UNSPSC

12352211

Target

Antibody-Drug Conjugates (ADCs) ; Antifolate

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mirvetuximab-soravtansine-solution.html

Purity

98.20

Solubility

10 mM in DMSO

Smiles

[Mirvetuximabsoravtansine(solution)]

Molecular Formula

C6482H10006N1714O2022S44 (C42H58ClN3O14S3) n

Molecular Weight

150000 (average)

References & Citations

[1]Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18 (12) :775-784.